Not one, not two, but three — biotech claims it will pursue CARs T, M and NK all at once
An oncology startup is touting some really, really bold claims.
Inceptor Bio announced its latest round of funding Thursday at $37 million, which it plans on using to back preclinical programs in CARs T, M and NK. Not only will it be fleshing out its oncology programs, the company says it will also be putting some of that financing to building out its manufacturing facility in Gainesville, FL, which it bought from Massachusetts CDMO Arranta Bio late last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.